A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands

Advances in genomic analyses enable the identification of new proteins that are associated with disease. To validate these targets, tool molecules are required to demonstrate that a ligand can have a disease‐modifying effect. Currently, as tools are reported for only a fraction of the proteome, plat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Angewandte Chemie International Edition 2020-11, Vol.59 (47), p.21096-21105
Hauptverfasser: Grant, Emma K., Fallon, David J., Hann, Michael M., Fantom, Ken G. M., Quinn, Chad, Zappacosta, Francesca, Annan, Roland S., Chung, Chun‐wa, Bamborough, Paul, Dixon, David P., Stacey, Peter, House, David, Patel, Vipulkumar K., Tomkinson, Nicholas C. O., Bush, Jacob T.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 21105
container_issue 47
container_start_page 21096
container_title Angewandte Chemie International Edition
container_volume 59
creator Grant, Emma K.
Fallon, David J.
Hann, Michael M.
Fantom, Ken G. M.
Quinn, Chad
Zappacosta, Francesca
Annan, Roland S.
Chung, Chun‐wa
Bamborough, Paul
Dixon, David P.
Stacey, Peter
House, David
Patel, Vipulkumar K.
Tomkinson, Nicholas C. O.
Bush, Jacob T.
description Advances in genomic analyses enable the identification of new proteins that are associated with disease. To validate these targets, tool molecules are required to demonstrate that a ligand can have a disease‐modifying effect. Currently, as tools are reported for only a fraction of the proteome, platforms for ligand discovery are essential to leverage insights from genomic analyses. Fragment screening offers an efficient approach to explore chemical space. Presented here is a fragment‐screening platform, termed PhABits (PhotoAffinity Bits), which utilizes a library of photoreactive fragments to covalently capture fragment–protein interactions. Hits can be profiled to determine potency and the site of crosslinking, and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is envisioned to be widely applicable to novel protein targets, identifying starting points in the development of therapeutics. PhotoAffinity Bit (PhABit) is a photoreactive fragment‐screening platform to covalently capture fragment–protein interactions. Hits can be profiled and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is widely applicable to novel protein targets, identifying starting points in the development of therapeutics.
doi_str_mv 10.1002/anie.202008361
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2458744828</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2458744828</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4501-4eed27f126176d535809f57b42301ff70b3a5c83cb5727ae7f8f3d2d3708a4fb3</originalsourceid><addsrcrecordid>eNqFkMtOAjEYhRujEUS3Lk0T14O9TssSDSgJURJ13XRmWixhWuwMMex8BJ_RJ7EExKWb_5bvnD85AFxi1McIkRvtnekTRBCSNMdHoIs5wRkVgh6nmVGaCclxB5w1zSLxUqL8FHQoEYwnvgvMEM7eQhu0tc67dvP9-XWrG1PBcdTz2vg2HZ7LaIx3fg5nS93aEGuYChwlSekSAidVqi5tunXBw2DhLIbWOA-nbq591ZyDE6uXjbnY9x54HY9e7h6y6dP95G44zUrGEc6YMRURFpMci7zilEs0sFwUjFCErRWooJqXkpYFF0RoI6y0tCIVFUhqZgvaA9c731UM72vTtGoR1tGnl4owLgVjkshE9XdUGUPTRGPVKrpax43CSG1TVdtU1SHVJLja266L2lQH_DfGBAx2wIdbms0_dmr4OBn9mf8AsqKFzw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2458744828</pqid></control><display><type>article</type><title>A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Grant, Emma K. ; Fallon, David J. ; Hann, Michael M. ; Fantom, Ken G. M. ; Quinn, Chad ; Zappacosta, Francesca ; Annan, Roland S. ; Chung, Chun‐wa ; Bamborough, Paul ; Dixon, David P. ; Stacey, Peter ; House, David ; Patel, Vipulkumar K. ; Tomkinson, Nicholas C. O. ; Bush, Jacob T.</creator><creatorcontrib>Grant, Emma K. ; Fallon, David J. ; Hann, Michael M. ; Fantom, Ken G. M. ; Quinn, Chad ; Zappacosta, Francesca ; Annan, Roland S. ; Chung, Chun‐wa ; Bamborough, Paul ; Dixon, David P. ; Stacey, Peter ; House, David ; Patel, Vipulkumar K. ; Tomkinson, Nicholas C. O. ; Bush, Jacob T.</creatorcontrib><description>Advances in genomic analyses enable the identification of new proteins that are associated with disease. To validate these targets, tool molecules are required to demonstrate that a ligand can have a disease‐modifying effect. Currently, as tools are reported for only a fraction of the proteome, platforms for ligand discovery are essential to leverage insights from genomic analyses. Fragment screening offers an efficient approach to explore chemical space. Presented here is a fragment‐screening platform, termed PhABits (PhotoAffinity Bits), which utilizes a library of photoreactive fragments to covalently capture fragment–protein interactions. Hits can be profiled to determine potency and the site of crosslinking, and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is envisioned to be widely applicable to novel protein targets, identifying starting points in the development of therapeutics. PhotoAffinity Bit (PhABit) is a photoreactive fragment‐screening platform to covalently capture fragment–protein interactions. Hits can be profiled and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is widely applicable to novel protein targets, identifying starting points in the development of therapeutics.</description><edition>International ed. in English</edition><identifier>ISSN: 1433-7851</identifier><identifier>EISSN: 1521-3773</identifier><identifier>DOI: 10.1002/anie.202008361</identifier><identifier>PMID: 32745361</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Antineoplastic Agents - analysis ; Antineoplastic Agents - pharmacology ; Bridged Bicyclo Compounds, Heterocyclic - analysis ; Bridged Bicyclo Compounds, Heterocyclic - pharmacology ; covalent ; Cross-Linking Reagents - chemistry ; Crosslinking ; Drug development ; drug discovery ; Genomic analysis ; Humans ; inhibitors ; Ligands ; Molecular Structure ; photoaffinity ; Photoaffinity Labels - chemistry ; Protein interaction ; Proteins ; Proteins - antagonists &amp; inhibitors ; Proteins - chemistry ; Proteomes ; Pyrazoles - analysis ; Pyrazoles - pharmacology ; Quinoxalines - analysis ; Quinoxalines - pharmacology ; Screening ; Sulfonamides - analysis ; Sulfonamides - pharmacology ; Vemurafenib - analysis ; Vemurafenib - pharmacology</subject><ispartof>Angewandte Chemie International Edition, 2020-11, Vol.59 (47), p.21096-21105</ispartof><rights>2020 Wiley‐VCH GmbH</rights><rights>2020 Wiley-VCH GmbH.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4501-4eed27f126176d535809f57b42301ff70b3a5c83cb5727ae7f8f3d2d3708a4fb3</citedby><cites>FETCH-LOGICAL-c4501-4eed27f126176d535809f57b42301ff70b3a5c83cb5727ae7f8f3d2d3708a4fb3</cites><orcidid>0000-0001-7165-0092</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fanie.202008361$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fanie.202008361$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32745361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grant, Emma K.</creatorcontrib><creatorcontrib>Fallon, David J.</creatorcontrib><creatorcontrib>Hann, Michael M.</creatorcontrib><creatorcontrib>Fantom, Ken G. M.</creatorcontrib><creatorcontrib>Quinn, Chad</creatorcontrib><creatorcontrib>Zappacosta, Francesca</creatorcontrib><creatorcontrib>Annan, Roland S.</creatorcontrib><creatorcontrib>Chung, Chun‐wa</creatorcontrib><creatorcontrib>Bamborough, Paul</creatorcontrib><creatorcontrib>Dixon, David P.</creatorcontrib><creatorcontrib>Stacey, Peter</creatorcontrib><creatorcontrib>House, David</creatorcontrib><creatorcontrib>Patel, Vipulkumar K.</creatorcontrib><creatorcontrib>Tomkinson, Nicholas C. O.</creatorcontrib><creatorcontrib>Bush, Jacob T.</creatorcontrib><title>A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands</title><title>Angewandte Chemie International Edition</title><addtitle>Angew Chem Int Ed Engl</addtitle><description>Advances in genomic analyses enable the identification of new proteins that are associated with disease. To validate these targets, tool molecules are required to demonstrate that a ligand can have a disease‐modifying effect. Currently, as tools are reported for only a fraction of the proteome, platforms for ligand discovery are essential to leverage insights from genomic analyses. Fragment screening offers an efficient approach to explore chemical space. Presented here is a fragment‐screening platform, termed PhABits (PhotoAffinity Bits), which utilizes a library of photoreactive fragments to covalently capture fragment–protein interactions. Hits can be profiled to determine potency and the site of crosslinking, and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is envisioned to be widely applicable to novel protein targets, identifying starting points in the development of therapeutics. PhotoAffinity Bit (PhABit) is a photoreactive fragment‐screening platform to covalently capture fragment–protein interactions. Hits can be profiled and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is widely applicable to novel protein targets, identifying starting points in the development of therapeutics.</description><subject>Antineoplastic Agents - analysis</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Bridged Bicyclo Compounds, Heterocyclic - analysis</subject><subject>Bridged Bicyclo Compounds, Heterocyclic - pharmacology</subject><subject>covalent</subject><subject>Cross-Linking Reagents - chemistry</subject><subject>Crosslinking</subject><subject>Drug development</subject><subject>drug discovery</subject><subject>Genomic analysis</subject><subject>Humans</subject><subject>inhibitors</subject><subject>Ligands</subject><subject>Molecular Structure</subject><subject>photoaffinity</subject><subject>Photoaffinity Labels - chemistry</subject><subject>Protein interaction</subject><subject>Proteins</subject><subject>Proteins - antagonists &amp; inhibitors</subject><subject>Proteins - chemistry</subject><subject>Proteomes</subject><subject>Pyrazoles - analysis</subject><subject>Pyrazoles - pharmacology</subject><subject>Quinoxalines - analysis</subject><subject>Quinoxalines - pharmacology</subject><subject>Screening</subject><subject>Sulfonamides - analysis</subject><subject>Sulfonamides - pharmacology</subject><subject>Vemurafenib - analysis</subject><subject>Vemurafenib - pharmacology</subject><issn>1433-7851</issn><issn>1521-3773</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtOAjEYhRujEUS3Lk0T14O9TssSDSgJURJ13XRmWixhWuwMMex8BJ_RJ7EExKWb_5bvnD85AFxi1McIkRvtnekTRBCSNMdHoIs5wRkVgh6nmVGaCclxB5w1zSLxUqL8FHQoEYwnvgvMEM7eQhu0tc67dvP9-XWrG1PBcdTz2vg2HZ7LaIx3fg5nS93aEGuYChwlSekSAidVqi5tunXBw2DhLIbWOA-nbq591ZyDE6uXjbnY9x54HY9e7h6y6dP95G44zUrGEc6YMRURFpMci7zilEs0sFwUjFCErRWooJqXkpYFF0RoI6y0tCIVFUhqZgvaA9c731UM72vTtGoR1tGnl4owLgVjkshE9XdUGUPTRGPVKrpax43CSG1TVdtU1SHVJLja266L2lQH_DfGBAx2wIdbms0_dmr4OBn9mf8AsqKFzw</recordid><startdate>20201116</startdate><enddate>20201116</enddate><creator>Grant, Emma K.</creator><creator>Fallon, David J.</creator><creator>Hann, Michael M.</creator><creator>Fantom, Ken G. M.</creator><creator>Quinn, Chad</creator><creator>Zappacosta, Francesca</creator><creator>Annan, Roland S.</creator><creator>Chung, Chun‐wa</creator><creator>Bamborough, Paul</creator><creator>Dixon, David P.</creator><creator>Stacey, Peter</creator><creator>House, David</creator><creator>Patel, Vipulkumar K.</creator><creator>Tomkinson, Nicholas C. O.</creator><creator>Bush, Jacob T.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0001-7165-0092</orcidid></search><sort><creationdate>20201116</creationdate><title>A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands</title><author>Grant, Emma K. ; Fallon, David J. ; Hann, Michael M. ; Fantom, Ken G. M. ; Quinn, Chad ; Zappacosta, Francesca ; Annan, Roland S. ; Chung, Chun‐wa ; Bamborough, Paul ; Dixon, David P. ; Stacey, Peter ; House, David ; Patel, Vipulkumar K. ; Tomkinson, Nicholas C. O. ; Bush, Jacob T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4501-4eed27f126176d535809f57b42301ff70b3a5c83cb5727ae7f8f3d2d3708a4fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antineoplastic Agents - analysis</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Bridged Bicyclo Compounds, Heterocyclic - analysis</topic><topic>Bridged Bicyclo Compounds, Heterocyclic - pharmacology</topic><topic>covalent</topic><topic>Cross-Linking Reagents - chemistry</topic><topic>Crosslinking</topic><topic>Drug development</topic><topic>drug discovery</topic><topic>Genomic analysis</topic><topic>Humans</topic><topic>inhibitors</topic><topic>Ligands</topic><topic>Molecular Structure</topic><topic>photoaffinity</topic><topic>Photoaffinity Labels - chemistry</topic><topic>Protein interaction</topic><topic>Proteins</topic><topic>Proteins - antagonists &amp; inhibitors</topic><topic>Proteins - chemistry</topic><topic>Proteomes</topic><topic>Pyrazoles - analysis</topic><topic>Pyrazoles - pharmacology</topic><topic>Quinoxalines - analysis</topic><topic>Quinoxalines - pharmacology</topic><topic>Screening</topic><topic>Sulfonamides - analysis</topic><topic>Sulfonamides - pharmacology</topic><topic>Vemurafenib - analysis</topic><topic>Vemurafenib - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grant, Emma K.</creatorcontrib><creatorcontrib>Fallon, David J.</creatorcontrib><creatorcontrib>Hann, Michael M.</creatorcontrib><creatorcontrib>Fantom, Ken G. M.</creatorcontrib><creatorcontrib>Quinn, Chad</creatorcontrib><creatorcontrib>Zappacosta, Francesca</creatorcontrib><creatorcontrib>Annan, Roland S.</creatorcontrib><creatorcontrib>Chung, Chun‐wa</creatorcontrib><creatorcontrib>Bamborough, Paul</creatorcontrib><creatorcontrib>Dixon, David P.</creatorcontrib><creatorcontrib>Stacey, Peter</creatorcontrib><creatorcontrib>House, David</creatorcontrib><creatorcontrib>Patel, Vipulkumar K.</creatorcontrib><creatorcontrib>Tomkinson, Nicholas C. O.</creatorcontrib><creatorcontrib>Bush, Jacob T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>Angewandte Chemie International Edition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grant, Emma K.</au><au>Fallon, David J.</au><au>Hann, Michael M.</au><au>Fantom, Ken G. M.</au><au>Quinn, Chad</au><au>Zappacosta, Francesca</au><au>Annan, Roland S.</au><au>Chung, Chun‐wa</au><au>Bamborough, Paul</au><au>Dixon, David P.</au><au>Stacey, Peter</au><au>House, David</au><au>Patel, Vipulkumar K.</au><au>Tomkinson, Nicholas C. O.</au><au>Bush, Jacob T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands</atitle><jtitle>Angewandte Chemie International Edition</jtitle><addtitle>Angew Chem Int Ed Engl</addtitle><date>2020-11-16</date><risdate>2020</risdate><volume>59</volume><issue>47</issue><spage>21096</spage><epage>21105</epage><pages>21096-21105</pages><issn>1433-7851</issn><eissn>1521-3773</eissn><abstract>Advances in genomic analyses enable the identification of new proteins that are associated with disease. To validate these targets, tool molecules are required to demonstrate that a ligand can have a disease‐modifying effect. Currently, as tools are reported for only a fraction of the proteome, platforms for ligand discovery are essential to leverage insights from genomic analyses. Fragment screening offers an efficient approach to explore chemical space. Presented here is a fragment‐screening platform, termed PhABits (PhotoAffinity Bits), which utilizes a library of photoreactive fragments to covalently capture fragment–protein interactions. Hits can be profiled to determine potency and the site of crosslinking, and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is envisioned to be widely applicable to novel protein targets, identifying starting points in the development of therapeutics. PhotoAffinity Bit (PhABit) is a photoreactive fragment‐screening platform to covalently capture fragment–protein interactions. Hits can be profiled and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is widely applicable to novel protein targets, identifying starting points in the development of therapeutics.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32745361</pmid><doi>10.1002/anie.202008361</doi><tpages>10</tpages><edition>International ed. in English</edition><orcidid>https://orcid.org/0000-0001-7165-0092</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1433-7851
ispartof Angewandte Chemie International Edition, 2020-11, Vol.59 (47), p.21096-21105
issn 1433-7851
1521-3773
language eng
recordid cdi_proquest_journals_2458744828
source MEDLINE; Access via Wiley Online Library
subjects Antineoplastic Agents - analysis
Antineoplastic Agents - pharmacology
Bridged Bicyclo Compounds, Heterocyclic - analysis
Bridged Bicyclo Compounds, Heterocyclic - pharmacology
covalent
Cross-Linking Reagents - chemistry
Crosslinking
Drug development
drug discovery
Genomic analysis
Humans
inhibitors
Ligands
Molecular Structure
photoaffinity
Photoaffinity Labels - chemistry
Protein interaction
Proteins
Proteins - antagonists & inhibitors
Proteins - chemistry
Proteomes
Pyrazoles - analysis
Pyrazoles - pharmacology
Quinoxalines - analysis
Quinoxalines - pharmacology
Screening
Sulfonamides - analysis
Sulfonamides - pharmacology
Vemurafenib - analysis
Vemurafenib - pharmacology
title A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T13%3A24%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Photoaffinity%E2%80%90Based%20Fragment%E2%80%90Screening%20Platform%20for%20Efficient%20Identification%20of%20Protein%20Ligands&rft.jtitle=Angewandte%20Chemie%20International%20Edition&rft.au=Grant,%20Emma%20K.&rft.date=2020-11-16&rft.volume=59&rft.issue=47&rft.spage=21096&rft.epage=21105&rft.pages=21096-21105&rft.issn=1433-7851&rft.eissn=1521-3773&rft_id=info:doi/10.1002/anie.202008361&rft_dat=%3Cproquest_cross%3E2458744828%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2458744828&rft_id=info:pmid/32745361&rfr_iscdi=true